FDA looks to update drug database

In an effort to update a woefully outdated national drug registry, the FDA is floating new regulations that would require drug makers to submit information electronically to the agency. The database is used to track recalls and provides information to insurers on reimbursing pharmaceutical expenses. A recent audit of the information, though, found tens of thousands of mistakes on the 124,000 drugs listed. Currently, the information for the database has to be input by hand.

- read The Wall Street Journal report on the database (sub. req.)

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.